Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial (updated)

LeonaBio

03/09/2024 21:31

(Adds trial details in paragraphs 2 and 5)
       Sept 3 (Reuters) - Athira Pharma  ATHA.O  said on
Tuesday its drug failed to meet the main goal in a mid-to-late
stage trial in patients with mild-to-moderate Alzheimer's
disease.
    The experimental drug, fosgonimeton, failed to reach
statistical significance in a test that measures cognition and
other functions, compared to placebo at 26 weeks.
        "These are not the results we hoped for,"  said Chief
Medical Officer Javier Martin.
        The lack of clinical decline in the placebo group,
combined with the short duration of the study, may have impacted
the trial's ability to translate the effect of fosgonimeton into
meaningful benefit, Martin added.
    The trial evaluated the efficacy and safety of once-daily
injections of fosgonimeton in 312 patients.
        
  

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini
Ganguli)
 ((Sriparna.Roy@thomsonreuters.com;))